DexCom Inc., a San Diego-based medical device company, reported its unaudited financial results for the quarter ended Sept. 30, 2014.

Product revenue grew to $67.9 million for the third quarter of 2014, an increase of 60 percent from the $42.5 million in product revenue reported for the third quarter of 2013. Total revenue grew to $69 million for the third quarter of 2014, an increase of 61 percent from the same quarter in 2013. Product gross profit totaled $46.1 million for the third quarter, compared to a product gross profit of $27.7 million for the same quarter last year.

DexCom (Nasdaq: DXCM) reported a net loss of $5.2 million, or $0.07 per share, for the third quarter, compared to a net loss of $6 million in the third quarter of 2013.

Research and development expenses increased by approximately $6.7 million to $18.5 million for the third quarter of 2014 compared to $11.8 million for the third quarter of last year. Selling, general and administrative expenses increased by approximately $12.1 million to $33.7 million for the third quarter of 2014 compared to $21.6 million for the third quarter of 2013.

As of Sept. 30, 2014, the company had $74.9 million in cash and marketable securities.